The Recall Desk
HighFDA (Drugs)·D-0251-2026·Announced 2026-01-14

Tri-Moxi intraocular injection recalled over glass-like particulate matter

Imprimis NJOF is recalling 314 boxes containing 6,280 pre-filled syringes of Tri-Moxi triamcinolone and moxifloxacin intraocular injection over glass-like particles.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: Scored 3 under the risk-of-harm criterion: glass-like particles in an intraocular injection are a stated contaminant, and no injuries are reported.

Plain-English summary

Tri-Moxi (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, from Imprimis NJOF, LLC of Ledgewood, New Jersey, under NDC 71384-746-06, is being recalled.

The reason given in the enforcement record is the presence of particulate matter, described as glass-like particles.

The recall covers 314 boxes of 6,280 pre-filled syringes from lots 25JAN033A and 25JAN033B, expiring 02/12/2026. Distribution was nationwide in the US. The FDA has classified the action as Class II.

Glass-like particles in a product injected into the eye are a stated physical contaminant. Facilities should quarantine affected lots and follow the firm's instructions.

The recalled product

Product
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
Manufacturer
Imprimis NJOF, LLC
Category
Drug — Intraocular injection
Hazard
  • particulate-matter
  • glass-particles
  • ophthalmic
  • compounded

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (3)

  • Lot: 25JAN033A
  • 25JAN033B
  • Expires: 02/12/2026.

Distribution

Distributed nationwide across the United States.

Related recalls

Same category